* Celgene Corp., of Warren, N.J., said research it did with scientistsat Rockefeller University showed novel derivatives of thalidomideappear to be effective in controlling a potentially destructive immuneresponse. The research appears in the July issue of MolecularMedicine.

* MediChem Research Inc., of Lemont, Ill., was awarded a $100,000Small Business Innovation Research grant to synthesize non-chiralanalogues of the natural product michellamine B as novel anti-HIV-1and HIV-2 agents. The synthetic analogues will be evaluated for theircytoprotective capacity and their cytotoxicity in the cell lines toestablish indices for the compounds.

* MGI Pharma Inc., of Minnetonka, Minn., said the National CancerInstitute voted in favor of funding and conducting human trials ofMGI 114, the lead analogue from MGI's acylfulvene family of anti-cancer compounds. The deal is pending execution of a clinical trialsagreement.

* NeoPharm Inc., of Lake Forest, Ill., said it will file by the end ofthis year two new drug applications for Broxuridine for treatment ofbrain cancer and detection of breast cancer. Broxuridine is aradiosensitizer designed to enhance the effectiveness of radiationtherapy.

* Sequus Pharmaceuticals Inc., of Menlo Park, Calif., said the FDAapproved an increase of shelf life time for Doxil, or liposomaldoxorubicin, from 14 to 20 months. The product is approved fortreatment of Kaposi's sarcoma.

* Scios Inc., of Mountain View, Calif., said partner KakenPharmaceutical Co. Ltd., of Tokyo, submitted a new drug applicationin Japan for Fiblast (basic fibroblast growth factor) for treatment ofrecalcitrant dermal ulcers. The filing is the first for a Scios-discovered product.

* Sibia Neurosciences Inc., of La Jolla, Calif., signed an agreementwith Cognetix Inc., of Salt Lake City, to conduct research onconopeptides, which are derived from the Conus species of marinesnails. They will try to identify selective compounds for receptorsand ion channels found on nerve cells, specifically recombinanthuman nicotinic acetylcholine receptor subtypes. The agreementprovides Sibia consideration of an exclusive, worldwide license tointellectual property and specific molecules from the work.

(c) 1997 American Health Consultants. All rights reserved.

No Comments